Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Of the 10 patients who had received one line of prior treatment, an objective response rate of 100% was recorded.
Darren Incorvaia
Jun 13, 2025 1:22pm
Protara gears up for next commercial steps—Chutes & Ladders
Jun 6, 2025 8:30am
Tariff-driven uncertainty rattles medtech industry
Jun 3, 2025 10:40am
J&J shares survival data on KLK2 bispecific in prostate cancer
Jun 2, 2025 6:40am
Gilgamesh links psychedelic to 94% remission rate in depression
May 27, 2025 11:00am
J&J trials IVL-first strategy in women with blocked coronaries
May 20, 2025 11:45am
